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CHSD
Centre for Health Service Development
Health Outcomes (Australia)
EBM
CQA
PopH
ACE
CQI
CPI HRQOL
HO i t i A t li h lth ti i t d more encompass ng erm n us ra a - ea  prac ce mprovemen  an  
better patient outcomes are the common threads
Health O tcomes foc s on se of HRQOL and health stat s meas rement u  – u   u      u  u  
for
 population health surveys   
 to evaluate the effects of health interventions and to monitor patient 
outcomes at the clinical level and     
 for pharmaceutical registration and reimbursement (PBS) 
National Health Survey  
 First inclusion of patient rated health status measure other than a global 
it SF 36 (1995) SF 12 (1997) K l 10 t l h lthem – -  ; -   ess er  men a  ea  screener 
(2001, 2004, 2008)
 Surveys also contain items on health conditions service use health      ,  ,  
behaviours, socio-demographic aspects
 Value seen in  identifying disease profiles for self reported health 
conditions, and for across disease comparisons. Provides useful 
normative data 
 Not much analysis of health related actions/service use in relation to           
SF-36 in 1995 
 Other later, related, projects confirmed previous associations of SF-36         
with survival, future health, health utilization/expenditures etc.
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Instruments Used: Major Health Surveys    
SF-36V1 (PSM 1995, NHS 95, WHA, CCHOP, State Surveys)
 SF-12, GHQ12, Kessler 10, CIDI (NMHWBS 1997)
EQ-5D (NSW 1998 – note recent UK developments)
Kessler -10 (NSW 1998 NHS 2001 2004 2008; 45 and up)   ,  , ,    
 SF-36V2 (SAHOS 2004)
A j l h b th i i f ti d t ma or va ue as een e prov s on o  norma ve a a 
supporting clinical research and the use of surveys to 
t i l i t t f d HO h dr a  some ns rumen s or propose   researc  an  
monitoring initiatives
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Women’s Health Australia  
 20-year longitudinal cohort study of the health and well-
being of Australian women, Newcastle & Queensland Unis
 Commenced 1996 and continuing
 Funded by Commonwealth Dept. of Health & Ageing
 Postal surveys and linkage to Medicare database
 Social view of health: 
physical health and symptoms, emotional well-being
health service use, access and satisfaction, demographics
health behaviours, time use, life events
Web site is at www.newcastle.edu.au/centre/wha
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Goal
 to determine social, psychological, physical and 
environmental factors which determine health among in       
women throughout adult life 
 to contribute to the development of policy and practice in key 
areas for women’s health
National Health Priority Areas - diabetes, asthma …
H lth T t A i W ll C ti Q lit U f M di iea  arge s e.g. ge ng e , on nence,  ua y se o  e c nes, 
National Tobacco Strategy, Watching Australia’s Weight, Active 
Australia …
 Cohorts = Young (18-25) Mid (45-50) Older (70-75) at 
commencement (1996). Cohorts 12,500 – 14,000 with high 
retention rates follow up 3 - 5 years longitudinal ,      ….  
‘snapshots’
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Stiff or Painful Joints and Change in 
SF-36 Physical Health: Mid and Older  Women
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Health Service Delivery: Coordinated Care Trials     
 Trials which examined ‘fund pooling’ models to provide 
coordinated care for elderly with chronic conditions vs. usual GP 
care
 H th i d t i t i t i / l t fypo es ze  o mprove ou comes… or ma n a n  s ow ra e o  
decline – given nature of trial population?
 SF 36 used to monitor outcomes of all comparison/control-         
groups; disease specific measures and patient satisfaction were 
unique to each particular trial    
 Few SF-36 differences detected – no surprise given subtle nature 
of intervention - access to services ? and timeframe ?? 
 Conclusions reflect poor understanding of HRQOL assessment?
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Clinical Monitoring: Mental Health   
Review of consumer outcome measures – Andrews et 
al, 1994
Small trial of potential consumer measures (BASIS, 
MHI, SF-36) and provider measures (HoNOS, LSP, 
RFS)
Development of MH Classification and Service Costs 
Project MH-CASC (HoNOS, LSP, RUGS-ADL). 
Routine Implementation – HoNOS, LSP for all 
inpatients plus chosen consumer measure (K-10, 
BASIS, MHI)  - latter also used for outpatients
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Clinical Monitoring
Benchmarking of  service comparisons – outcomes 
results adjusted for patient mix - Casemix Adjusted 
R l ti M I t (CARMI) b t ie a ve ean mprovemen  ….. u  some ssues
? HoNOS - assumed predictor of cost also a good 
di t f tpre c or o  ou come
Is a clinician severity rating measure a good measure for 
it i ti t t ti ?mon or ng pa en  ou comes over me
Australian Rehabilitation Outcomes Centre (AROC) -
Similar benchmarking initiatives in rehabilitation (FIM)      
web enabling
I f l i f db k i i l f li i lssues o  rea  t me ee ac  are cr t ca  or c n ca  use, 
static databases are not the answer
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The Continuum of Care and Health 
Outcomes Project 
A longitudinal study of 7154 inpatients including both 
retrospective and prospective data (1995-96)
Develop profiles on health outcomes, care, service use 
and financial costs
Compare various patient and population groups in their 
service use and health outcomes    
Use the findings to help clinicians and 
administrators improve their decision making -     
implement and develop outcomes management model
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CCHOP to DiscoverQuick  
 N d t t li t f i ti dee  o s ream ne sys em or use n rou ne care an  
research settings
 DiscoverQuick is a web enabled intelligent knowledge       
management system for outcomes management - providing 
real time feedback to clinicians 
 Allows recruitment to RCTs and HSR studies while 
providing support for patient care
 Integrates EBM knowledge bases guidelines in developing   , ,   
decision support algorithms
 Includes HRQOL data with settings which can be linked to         
instrument review repositories and provide feedback to 
these
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HRQOL: Needs Assessment  
Community and Primary Care -Initial Needs Assessment, 
Ongoing Needs Assessment, Health and Community 
Care Screening, Aged Care Assessment, Provision of 
Appliances for Disabled Persons
Tiered approaches, screening and follow up assessment 
to determine needs and assign services
Use of ADL and IADL functional skills profiles (Modified         
Barthel, FIM, Lawton’s IADL)
Mainly needs assessment but also for outcomes       
monitoring in some projects
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Aged Care Assessment  
• Desire to standardise aged care assessments 
nationally – great goals - given the diversity of 
these assessments 
• Screening and follow up assessments
• Ensure all clients receive a cognitive assessment
• Desire for valid and reliable assessment but     …….  
do committee choices really reflect this aspect?
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Summary of Ratings for Cognitive Assessment Instruments
Criteria
Weight MMMSE 
(3MS)
SMMSE RUDASa KICA-
COG
KICA-
CARER
IQCODE
Theoretical/empirical basis 3 3 3 3 3 3 3
Availability of comparison data 3 3 2 2 2 2 2
Length/feasibility of instrument for 
inclusion in battery
2 2 3 2 2 3 2
  
Complexity of administration/ 
cognitive burden 
2 2 2 2 3 3 3
Cultural Appropriateness 1 2 2 3 3 3 2 
Ease of obtaining score 2 2.5 2.5 3 3 3 3
Sensitivity 3 3 2.5 2 2 2 2.5
Reliability evidence 3 3 3 3 2 5b 2b 3  .
Validity evidence 3 3 3 2.5b 2.5b 2b 3
Cost of the instrument 2 3 2c 2 3 3 3
Cost of instrument administration  2 2 2 2 2 2 2
Weighted Total 70 65.5 62.5 65 64 68.5
Based on the DOMs review in 2008 – this review needs to be updated
b. Scored as 2 or 2.5 because of there being limited evidence/publications or independent publications but what there is indicates good sensitivity, validity and/or reliability.
c. Rated as 2 vs.1 as the costs are minimal and estimated at 12 cents per use
From Sansoni J et al.(2010) Selecting Tools for ACAT Assessment: A Report for the Aged Care Assessment Progam (ACAP) Expert Clinical Reference Group. CHSD, 
University of Wollongong. Report for the Aged Care Assessment Program, Australian Government Department of Health and Ageing, Canberra
SAHOS: User Pays Survey   
3000 sample community survey used by researchers 
and government
2004 survey compared utility measures EQ5D, AQOL, 
HUI3, SF-6DV2, 15D in relation to incontinence items 
and also deriving interim norms for SF-36V2
Also reflects earlier government interest in developing       
outcome measurement suites (e.g. dementia, 
continence)…standardizing use of   
measures/items…for clinical applications
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Regulatory Aspects: PBS  
 Pharmaceutical Benefit Scheme (PBS) 1992 – required to 
conduct economic evaluation (with a focus on outcomes        
including HRQOL) for drug registration to attract government 
subsidy
 Subsidised medicine prices capped with a patient co-payment 
@ $5.60 healthcare card, others $34.20
 Reference Pricing … a ‘me too’ drug price will be set at the 
price of the lowest comparable drug (CMA). To gain a higher 
price for a new drug one must show relative benefit per $ over             
existing drugs…CEA, CUA analyses
 HRQOL data particularly relevant for submissions for chronic 
conditions and need to justify psychometric properties of 
selected instruments (PBAC Guidelines)
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22From Wilson 2004
Pharmaceutical Benefits Scheme
Quality of economic evaluations - 67% had some 
methodological flaw (Hill et al 2000 analysis    ,  … , 
interpretation, est. comparative clinical efficacy, modeling)
More recent revisions of PBAC guidelines… but need for 
greater expertise and greater ‘genuine’ transparency?
Despite these issues – a very effective scheme for pricing
See www.health.gov.au/pbs
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Some Issues 
Plenty of use but sometimes not gaining as much value –
reflects lack of familiarity with assessment and interpretation        
of HRQOL data (e.g. reliability and validity rhetoric vs. reality)
Instrument selection issues need to relate to purpose of   …       
assessment, develop more wisdom concerning the use of 
measures
Convenient/routine follow up assessment points may not 
always be the most informative    
Easier to collect data than to use it to inform practice
 HRQOL assessment issues may need more thought and the         
development of greater expertise
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Future Directions 
Becoming more sophisticated – and an 
increasing recognition of HRQOL measurement 
issues
A number of national (large scale) initiatives 
(e g 45 and up study WHA) and increasing. .    ,    
implementation in clinical practice
A focus on improving technology to facilitate       
outcomes monitoring and service comparisons 
f ti i tor prac ce mprovemen
25

Patient progress Vitality by time
Average Vitality Levels (+/- SD) over time 
comparing Patient against Group
27
Distribution of HRQoL utility scores by 
instrument
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